Thats true Refresher , I just think they are going to have plenty of choices , let me dredge up some old results from RT to illistrate what I mean .
<Diagnosis Count Avg. IC50 SEM
Sarcoma 8 5.69 1.10
Melanoma 3 6.13 1.93
Breast 7 6.76 1.36
Unidentified primary
site 4 6.83 1.58
Gastric
Intestinal 6 8.05 0.35
Ovarian 24 9.93 1.57
Non Small Cell Lung
Cancer 7 10.77 1.72
Total Combined Dx 68 8.34 0.65
From the data in table 2 it can be seen that SBP002 exhibits a wide range of activity across many tumor types with sarcoma, melanoma and breast being good targets. Upon further testing using the ex-vivo directed therapy model to determine the overall response rates shown for some of the above tumors, observations included:
Complete response was shown in 17%;
Partial response was shown in a further 40%; and
Overall response 57% >>
Looks like plenty of good targets there.
Cheers
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
